Company profile
Absci Corporation
NASDAQ: ABSI · Healthcare · Biotechnology
#765 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
47DFH 53DQ 40GM 39SS 56
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ operating margin, net margin
Methodology →Revenue TTM
$1.6M
Rev growth YoY (TTM)
-62.3%
Net income (FY)
-$115.2M
Employees
140
as of 2026-08-09
Market cap
$1.5B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.8M$2.8M2025
Net income-$115.2M-$115.2M2025
Operating income-$120.3M-$120.3M2025
Total assets$216.3M$216.3M2025
Liabilities$26.8M$26.8M2025
Equity$189.4M$189.4M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Absci Corporation’s revenue?
Absci Corporation booked $2.8M in FY2025 revenue, contracting 38% year over year — slower than 78% of Healthcare companies we track, at a -4113.7% net margin.
Peers · Healthcare
Upstream Bio, Inc.44DMedical Supply International USA, Inc.——RxElite, Inc.——Hypha Labs, Inc.35DQHSLab, Inc.70BInnovative Eyewear, Inc.45DNeighbors
Clark →Key facts
CEOSean McClain
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, WA
ExchangeNASDAQ: ABSI
Employees140
IPO date2021-07-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.